Spiramycin tablets 1.5M IU for congenital toxoplasmosis (Sanofi, toxoplasmosis, gondii, Rovamycin)
What are Spiramycin tablets 1.5MIU for congenital toxoplasmosis (gondii, Rovamycin)?
Spiramycin, classified as a macrolide antibiotic, serves a dual purpose as both an antibiotic and an antiparasitic agent. Functioning by impeding protein synthesis within bacterial and parasite cells, this compound exhibits efficacy against a spectrum of microorganisms, notably encompassing:
Cocci and rods categorized as Gram-positive.
- Gram-negative cocci.
- Legionellae bacteria.
- Chlamydiae pathogens.
- Specific strains of spirochetes.
- Cryptosporidium species.
- Toxoplasma gondii.
Of particular significance is Spiramycin's role in maternal health during pregnancy. The application of Spiramycin tablets is instrumental in mitigating the manifestations of congenital toxoplasmosis, a condition that can affect unborn infants. This medicinal intervention not only combats the presence of Toxoplasma gondii, the causative agent of toxoplasmosis, but also exerts a preventive influence against the transmission of toxoplasmosis across the placenta. By doing so, it substantially diminishes the probability of fetal infection.
Empirical investigations underscore the positive outcomes associated with Spiramycin administration to expectant mothers grappling with acute toxoplasmosis. Notably, a remarkable 94% of pregnant individuals, following Spiramycin treatment, exhibited the absence of amniotic fluid containing toxoplasma, further corroborating the compound's efficacy in curtailing intrauterine transmission.
In summary, Spiramycin's multifaceted antibiotic and antiparasitic properties equip it to counteract a diverse range of microorganisms. In the context of pregnancy, its use holds significant benefits, as it not only targets Toxoplasma gondii but also hampers the transmission of toxoplasmosis to the fetus. This evidence-based approach has shown substantial promise in safeguarding maternal and fetal well-being, fostering a safer gestational environment for both mother and child.
Active principles: spiramycin
Amount: 96 tablets
Maker: Sanofi K. K., Tokyo, Japan
Indications: suppress the symptoms of congenital toxoplasmosis in pregnant women
How to take
Pregnant women should take 2 tablets (3 millions IU of active principle) at a time, 3 times a day.
Contraindications: do not use for breastfeeding women.
If an allergic reaction occurs, patient needs to stop using the medicine and consult with their doctor. If patient is taking any other medication or treatment, they should consult with their doctor in advance.